• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » FDA approves Boston Scientific’s market-first wire-free pacemaker

FDA approves Boston Scientific’s market-first wire-free pacemaker

October 1, 2012 By MassDevice staff

Cameron Health's subcutaneous ICD

Boston Scientific (NYSE:BSX) and newly acquired Cameron Health won FDA approval for the world’s only commercially available lead-free implantable cardioverter defibrillator, the S-ICD.

Implanted just under the skin, the S-UCD is the only device of its kind that does not require wires threaded into the heart in order to provide therapy. The less-invasive device opens up the technology to a larger swath of patients.

Earlier this year an FDA expert panel voted 7-to-1 in favor of approval for the device, which Boston Scientific acquired in a merger with Cameron Health that’s worth up to $1.35 billion.

"With the addition of the S-ICD System, we believe Boston Scientific has a compelling and highly differentiated portfolio that will help fuel our growth strategy," Boston Scientific interim CEO Hank Kucheman said in prepared remarks. "We are the only company to offer an FDA-approved subcutaneous implantable defibrillator and expect this to be the case for several years."

The S-ICD system won CE Mark approval in the European Union in 2009 and has been on the market outside for some time. More than 1,400 devices have been implanted in patients around the world to date, according to a press release.

Boston Scientific expects to begin a phased launch of the S-ICD system that will expand over the time, the company announced.

"The S-ICD System provides an alternative for treating patients with life-threatening heart arrhythmias for whom the routine ICD placement procedure is not ideal," FDA Center for Devices & Radiological Health’s Office of Device Evaluation director Christy Foreman said in a prepared statement. "Some patients with anatomy that makes it challenging to place one of the implantable defibrillators currently on the market may especially benefit from this device."

That’s more good news for Boston Scientific as it continues gaining milestone in line with incoming CEO Mike Mahoney’s 2012-2013 development and regulatory approval time lines, which he shared during a conference call earlier this year.

"The S-ICD System, coupled with our numerous recent regulatory approvals and our other innovative products, such as the Watchman Left Atrial Appendage Closure Device and Alair Bronchial Thermoplasty System for the treatment of severe asthma, demonstrates our continued commitment to developing and bringing to market innovative products for physicians and their patients," Kucheman said in a prepared statement.

Mahoney is slated to take over as Boston Scientific president & CEO later this month.

The medical device titan is on a roll, having launched new heart and brain devices last week in Europe, MassHighTech reported.

Boston Scientific landed CE Mark approval in the European Union for its Vercise deep brain stimulation system, used in treatment of Parkinson’s disease, as well as European approval for the Emerge PTCA balloon catheter.

Filed Under: News Well, Pre-Market Approval (PMA) Tagged With: Boston Scientific, Cameron Health Inc., Cardiac Rhythm Management

More recent news

  • Comphya raises CHF 7.5 million for neurostim to treat ED
  • Fujifilm launches intelligent automation features for digital radiography
  • Integer appoints former iRhythm CEO to board
  • MMI debuts robotic surgery instruments, digital surgery platform
  • Synchrony Medical wins FDA nod for airway clearance system

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy